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As current clinical diagnostic protocols for Parkinson’s disease (PD) may be prone to 
inaccuracies there is a need to identify and validate molecular biomarkers, such as 
circulating microRNAs, which will complement current practices and increase diagnostic 
accuracy. This study identifies, verifies and validates combinatory serum microRNA 
signatures as diagnostic classifiers of PD across different patient cohorts.  
Methods 
370 PD (drug naïve) and control serum samples from the Norwegian ParkWest study 
were used for identification and verification of differential microRNA levels in PD which 
were validated in a blind study using 64 NY Parkinsonism in UMeå (NYPUM) study 
serum samples and tested for specificity in 48 Dementia Study of Western Norway 
(DemWest) study Alzheimer’s disease (AD) serum samples using miRNA-microarrays, 
and quantitative (q) RT-PCR. Proteomic approaches identified potential molecular targets 
for these microRNAs. 
Results  
Using Affymetrix GeneChip® miRNA 4.0 arrays and qRT-PCR we comprehensively 
analyzed serum microRNA levels and found that the microRNA (PARKmiR)-
combinations, hsa-miR-335-5p/hsa-miR-3613-3p (95% CI, 0.87-0.94), hsa-miR-335-
5p/hsa-miR-6865-3p (95% CI, 0.87-0.93), and miR-335-5p/miR-3613-3p/miR-6865-3p 
(95% CI, 0.87-0.94) show a high degree of discriminatory accuracy (AUC 0.9-1.0). The 
PARKmiR signatures were validated in an independent PD cohort (AUC ≤ 0.71) and 
analysis in AD serum samples showed PARKmiR signature specificity to PD. Proteomic 
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analyses showed that the PARKmiRs regulate key PD-associated proteins, including 
alpha-synuclein and Leucine Rich Repeat Kinase 2. 
Conclusions 
Our study has identified and validated unique miRNA serum signatures that represent PD 
classifiers, which may complement and increase the accuracy of current diagnostic 







Parkinson’s disease (PD) is the most common neurodegenerative movement disorder, 
characterized by neuronal cell death and Lewy bodies formation[1]. No molecular PD 
diagnostic tests exist and current diagnostic protocols, relying on disease presentation, 
treatment responses, and functional neuroimaging, are prone to diagnostic 
inaccuracies[2].  
MicroRNAs (miRNAs), have been associated with many neuronal processes and 
some show inappropriate regulation in a PD-specific manner including, miR-548d, miR-
224, miR-373, miR-198[3-6]. Circulating miRNAs may reflect cellular miRNA status 
where miRNA secretion and/or release into serum and plasma may involve active 
transport or release from apoptotic cells[7]. Studies have identified a number of miRNAs 
that show differential levels in PD including, miR-16 (blood/serum), miR-19a/b 
(CSF/blood), miR-29 members (blood), and miR-30 members (blood/serum)[6, 8, 9]. 
Recently, differential expression of circulating miRNAs (mir-103a, mir-30b, mir-29a) in 
L-dopa-treated PD patients was reported[10]. Although promising, the miRNAs were 
identified in relatively small PD cohorts, lacking validation, and by screening only a 
select number of miRNAs[3, 6, 8, 9].  
In this study we comprehensively screened 4603 human mature/pre-miRNAs and 
1996 human snoRNA/scaRNAs in order to identify miRNAs that show differential 
expression in PD patients. Utilizing a large longitudinal PD cohort of drug naïve patients 
with newly-diagnosed PD (n=180) and matched control subjects (n=190) from the 
Norwegian ParkWest study we verified a set of combinatory serum miRNA (PARKmiR) 
signatures that can act as robust classifiers of disease[11]. We further validated the 
PARKmiR signatures in an independent NY (new) Parkinsonism in UMeå (NYPUM) 
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study longitudinal cohort and tested for specificity in an Alzheimer’s Disease (AD) 
longitudinal cohort from the Dementia Study of Western Norway (DemWest study)[12, 
13]. We also performed proteome analysis in PARKmiR overexpressing SH-SY5Y 













Ethical parameters  
 The investigation was conducted in accordance with the ethical standards of the 
Declaration of Helsinki, and national and international guidelines on research with human 
subjects. Protocols were approved by the Western Norway Regional Committee for 
Medical and Health Research Ethics, the Regional Swedish Medical Ethical Review 
Board and the St. John’s University Institutional Review Board.  
 
Patients and controls from the Norwegian ParkWest study, the Swedish NYPUM 
study and the Norwegian DemWest study  
The Norwegian ParkWest and Swedish NYPUM studies are ongoing prospective 
population-based longitudinal PD cohort studies[11]. Patients with newly-diagnosed PD 
were recruited from Western and Southern Norway between November 1, 2004, and 
August 31, 2006, and from the Southern part of Västerbotten county in Northern Sweden 
between January 1, 2004 and April 30, 2009, respectively, to establish population-
representative incident PD cohorts[11, 12]. All 370 ParkWest and 64 NYPUM serum 
samples were obtained during baseline examination before dopaminergic treatment. 
Patients and controls are under ongoing follow-up and patients were included if they 
provided serum at baseline and fulfilled the National Institute of Neurological Disorders 
and Stroke and UK Brain Bank diagnostic criteria of PD at their final follow-up prior to 
this study.  
The Norwegian DemWest study recruited patients with mild dementia at time of 
diagnosis in Western Norway during 2005-2007 for a longitudinal cohort study[13]. 
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Patients were diagnosed as AD according to consensus criteria by The National Institute 
of Neurological and Communicative Disorders and Stroke-Alzheimer’s Disease and 
Related Disorders Association. 48 AD patients, age and gender matched with the 
ParkWest cohort, were selected.  
 All serum samples from all three cohorts were collected the same day as the clinical 
examinations and then stored at  -70oC until transported on dry ice to New York. 
 
RNA Isolation and cDNA synthesis  
 24 (16 PD and eight control) serum samples were centrifuged, the supernatant used 
for miRNA isolation, and the isolated RNA quantified on a Nanodrop 2000 (Thermo 
Scientific). cel-miR-39-3p (spike-in control) (Qiagen) was added to the RNA lysis buffer.  
 
miRNA microarray  
The isolated RNA from 16 patient and eight control serum samples (ParkWest study) 
were quantified and subjected to Affymetrix GeneChip® miRNA 4.0 Arrays containing 
4,603 human mature and pre-miRNAs and 1,996 human snoRNA/scaRNAs at the Yale 
Center for Genome Analysis (http://medicine.yale.edu/ keck/ycga/index.aspx) 
 
Data analysis of miRNA microarray 
 The normalized Affymetrix Expression Console software .CEL files were imported 
into Partek Genomics Suite version 6.6 Copyright  2012 (Partek, MO) for analysis. The 
24 Affymetrix Expression Console array files were analyzed using The Partek Genomics 
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Suite – microRNA Expression Workflow. Using ANOVA (a fold change of ≥ 1.4 and a 
p-value cutoff of <0.05) we determined differentially expressed miRNAs. 
 
Quantitative Reverse Transcriptase Polymerase Chain Reaction  
cDNA was synthesized following the manufacturer’s protocol and subsequent qRT-
PCRs were performed using miRNA specific primers (Supplemental Table 3) and 
PerfeCTa®Universal PCR primer (Quanta Biosciences). scaRNA17 was used as a 
reference small RNAs for normalizing qRT-PCR Cq values and cel-miR-39-3p (Qiagen) 
was used as a spike-in control. Standard curve for cel-miR-39-3p was analyzed in MS 
Excel with R2 = 0.98 and PCR efficiency 92.96%.  
 
Cell culture and transient cell transfection  
 SH-SY5Y cells (CRL-2266; ATCC) were cultured in a base medium mixture 
(Invitrogen) supplemented with 10% v/v fetal bovine serum (Atlanta biologics) and 2 
mM GlutaMAX (Invitrogen). Cells were transfected with scrambled control mimic, miR-
335-5p mimic, miR-3613-3p mimic, and miR-6865-3p mimic all mirVanaTM (Life 
Technologies) in triplicate as previously described[14]. AntagomiR transfections were 
carried out in similar manner. Cells were harvested after 24 hours for qRT-PCR analysis 
and after 48 hours for Western blotting and LC-MS analysis.  
 
RNA isolation, RT-PCR and quantitative PCR for neuroblastoma cells  
 RNA was isolated 24 hours post-transfection followed by cDNA synthesis and qRT-
PCR.   
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Western blotting  
 Whole cell lysates were prepared, using RIPA buffer 48 hours post-transfection, and 
used for Western blot analysis following published protocols[15]. Antibodies used were 
rabbit polyclonal anti-a-syn (Abcam, Cambridge, MA), rabbit polyclonal anti-LRRK2 
(Abcam, Cambridge, MA), mouse monoclonal anti-b-Actin (Sigma, St. Louis, MO) and 
rabbit polyclonal anti-GAPDH (Santa Cruz Biotechnology) along with the appropriate 
HRP-conjugated secondary antibody (Jackson Immu- noresearch, West Grove, PA). 
 
Sample preparation for liquid chromatography and mass spectrometry analysis  
 One million frozen cells were lysed and sonicated. The cleared lysate was trypsinized 
followed by drying and reconstitution in formic acid according to previous protocols[16].  
 
Liquid chromatography and mass spectrometry  
 Two µL of each sample (1 µg protein) were loaded onto a ReproSil-Pur C18-AQ 
beads self-packed column (Dr. Maisch GmbH, Germany). Peptides were eluted using a 
Thermo Scientific EASY-nLC 1000 coupled to a Q Exactive HF mass spectrometer 
(Thermo Fisher Scientific). The Q Exactive was operated in data-dependent analysis 
mode and up to the top 15 most abundant precursors were selected with an isolation 
window of 1.6 Thompsons and fragmented by higher-energy collisional dissociation. The 
raw files were processed using the MaxQuant[17] computational proteomics platform 
(version 1.2.7.0) for peptide identification and quantitation. The fragmentation spectra 
were searched against the UniProt human protein database (downloaded June 27, 2014). 
Both peptide and protein identifications were filtered at 1% false discovery rate (FDR).  
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Image analysis, statistical analysis, logistic regression analysis and contextual 
analysis  
Western blot images were analyzed using IQTL software (GE Healthcare) and 
Microsoft excel tools were used for two-tailed Student’s t-test. Predicted targets of miR-
335-5p and miR-3613-3p were used as input queries for the Partek Genomics Suite 
software, version 6.6 Copyright  2012 (Partek) to perform Gene ontology (GO) analysis 
and generate interactive maps and pathways. Label free quantification using mass 
spectrometry data was performed using the R language package (version 3.2.3). 
Significantly changed proteins between miRNA transfected and control cells were 
revealed by a t-test (threshold value p>0.01 and two-fold ratio).  
 The discriminative ability of miRNAs with regard to PD diagnosis was assessed from 
ROC analysis using IBM SPSS Statistics, version 21.  
 





Discovery of differentially expressed serum miRNAs in PD patients and controls  
In the discovery phase of this project we performed a miRNA microarray analysis 
employing serum samples from a subset of PD patients and control individuals 
participating in the ParkWest study[11]. We performed small RNA isolation on serum 
from 16 drug naïve PD patients and eight control individuals (Table 1), and following 
quality-control the RNA samples were analyzed using Affymetrix GeneChip® miRNA 
4.0 arrays. Using ANOVA we identified 23 human miRNAs (19 mature and 3 pre-
miRNAs) with a fold change of ≥ 1.4 and a p-value cutoff of <0.05 (Supplemental Table 
2). We selected a relatively low fold-change and p-value cutoff score to ensure that we 
captured a comprehensive list of differentially expressed miRNAs within the discovery 
phase of the project.  
 
Confirmation of the differentially expressed miRNAs  
As miRNA microarray screening may give rise to false positives the 24 serum 
samples used for the microarray screen were subjected to qRT-PCR assays using 
scaRNA17 as a reference small RNA and cel-miR-39-3p as a spike-in control. The spike-
in control was included to ensure the recovery of total small RNA was consistent across 
serum samples. From the 23 putative miRNAs in the discovery phase we confirmed that 
human mature miRNAs hsa-miR-335-5p, hsa-miR-3613-3p, and hsa-miR-6865-3p 
(PARKmiRs) were significantly upregulated in the 16 PD patients as compared to the 
eight control individuals suggesting that the three PARKmiRs may represent a miRNA 




Verification of the PARKmiRs in a large longitudinal cohort  
For the verification phase of this project we employed a qRT-PCR-based approach 
using 346 ParkWest serum samples (182 control and 164 newly-diagnosed, drug-naïve 
PD patients) (Table 1) and found that a combination of three PARKmiRs (hsa-miR-335-
5p, hsa-miR-3613-3p, hsa-miR-6865-3p) were robust classifiers of PD. Indeed, Receiver 
Operating Characteristic (ROC) curve analysis shows that the combinations, hsa-miR-
335-5p/hsa-miR-3613-3p (AUC 0.90, 95% CI 0.87 to 0.94), hsa-miR-335-5p/hsa-miR-
6865-3p (AUC 0.90, 95% CI 0.87 to 0.93), miR-335-5p/miR-3613-3p/miR-6865-3p 
(AUC 0.90, 95% CI 0.87 to 0.94), and to a lesser extent hsa-miR-3613-3p/hsa-miR-6865-
3p (AUC 0.74, 95% CI 0.69 to 0.80), can distinguish PD serum from control serum at the 
time of diagnosis (Fig. 1B-1F).  
 
Validation of the PARKmiRs in an independent cohort 
To validate the ParkWest discovery and verification phases we tested the PARKmiR 
signatures in 64 NYPUM study[12] serum samples (22 control and 42 newly-diagnosed, 
drug-naïve PD patients) (Table 1). All serum samples were subjected to identical assay 
conditions as in the verification phase and miRNA expression profiles were analyzed 
using ROC curve analysis. We validated that the PARKmiR combinations, miR-335-
5p/miR-3613-3p (AUC 0.75, 95% CI 0.63 to 0.87), miR-3613-3p/miR-6865-3p (AUC 
0.75, 95% CI 0.63 to 0.87), miR-335-5p/miR-6865-3p (AUC 0.71, 95% CI 0.59 to 0.84), 
and miR-335-5p/miR-3613-3p/miR-6865-3p (AUC 0.76, 95% CI 0.64 to 0.87), 
13 
 
significantly distinguished PD serum from control serum as observed in the ParkWest 
cohort (Fig. 2A-2E).  
Interestingly, miR-335-5p can distinguish PD serum from control serum in the 
ParkWest cohort (AUC 0.90, 95% CI 0.87 to 0.93) whilst in the NYPUM cohort miR-
335-5p was unable to differentiate PD from control serum (AUC 0.62, p = 0.125) 
(Supplemental Fig. 1). This suggests that single miRNA expression profile differences 
may not represent robust PD classifiers across different patient cohorts but rather that 
combinatory miRNA signatures are required.  
 
The PARKmiR signatures exhibit different profiles in AD patient serum  
 To ensure that the PARKmiR signatures showed specificity towards PD and not 
towards general neurodegeneration we tested the PARKmiR profiles in AD serum 
samples from the DemWest study[13]. 48 AD serum samples (Table 1) were subjected to 
RNA isolation, cDNA synthesis and qPCR analysis as in the verification phase. 
Interestingly, and in contrast to PD serum, the PARKmiRs displayed decreased levels in 
AD serum suggesting that the identified PARKmiR signatures show specificity towards 
PD (Fig. 3). Although the PD and AD serum samples were collected, processed, stored 
and analyzed in an identical manner, at the same clinical site, we corroborated the 
findings by performing qPCR analyses on the AD serum samples using U6 and miR-455-
3p as control targets. miR-455-3p was chosen as a control target as it did not show any 
significant differences in abundance between PD and control serum in the confirmation 
phase of the project. Our results demonstrate that both U6 and miR-455-3p show no 
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significant differences in abundance amongst control, PD and AD samples, confirming 
the integrity of the AD samples and dataset (Supplemental Fig. 2). 
 
In silico target prediction of the PARKmiRs 
Some miRNAs are deregulated in both biofluids and in brain tissue suggesting that 
perhaps the increase in serum PARKmiRs in PD may reflect PARKmiR secretion and/or 
release from apoptotic cells in the brain[3]. We therefore performed in silico prediction 
analyses to identify putative protein targets of the PARKmiRs using the Partek Genomics 
Suite, TargetScanHuman 6.2, DIANA TarBase, miRTarBase, miRecords, comiR and 
miRDB. We found that the PARKmiRs were predicted to target numerous proteins 
associated with fundamental neuronal processes with high enrichment scores (ES) 
including neurogenesis (18.3), neuronal developmental (14.8), differentiation (9.9), 
neurotransmitter secretion (6.1), and neurotransmitter transport (4.4) (Supplemental Fig. 
3).  
Interestingly, hsa-miR-335-5p may target LRRK2 and Parkin whereas hsa-miR-3613-
3p may target SNCA. No significant neuronal-associated protein targets were predicted 
for miR-6865-3p. To verify this we transfected mimics and antagomirs of hsa-miR-335-
5p, hsa-miR-3613-3p and hsa-miR-6865-3p into SH-SY5Y neuroblastoma cells (Fig. 4A, 
4D and 4H) followed by Western blotting. We found that the hsa-miR-335-5p mimic 
downregulates LRRK2 whilst inhibiting hsa-miR-335-5p leads to LRRK2 upregulation 
(Fig. 4B, 4C). Similarly, the miR-3613-3p mimic upregulates a-syn whilst the antagomir 
moderately downregulates a-syn (Fig. 4E, 4F). To corroborate these findings we found 
that a-syn mRNA levels are regulated by the hsa-miR-3613-3p mimic and antagomir 
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(Fig. 4G). By contrast, we did not find any significant regulation of Parkin in SH-SY5Y 
cells expressing the miR-335-5p mimic or antagomir. 
 
Protein target analysis of the PARKmiRs using LC-MS 
To complement the in silico analysis we subjected PARKmiR mimic- and control 
mimic-transfected SH-SY5Y cells (Fig. 4A, 4D and 4H) to LC-MS analysis. Out of 2,658 
proteins identified (Supplementary Dataset 1) 52 proteins (Supplemental Fig. 2, 
Supplemental Table 3) showed significant differences in abundance in response to 
PARKmiR expression compared to mimic control cells. In hsa-miR-335-5p, hsa-miR-
3613-3p, and hsa-miR-6865-3p mimic cells 18, 19, and 20 proteins showed statistically 
significant differential levels, respectively (Supplemental Table 3).  
miR-335-5p overexpression resulted in increased levels of E3 ubiquitin ligase hectd1 
(Supplemental Table 3) and miR-6865-3p overexpression resulted in increased 
abundance of the ubiquitin pathway proteins ube2h, ube3c, ube4b and ube2a 
(Supplemental Table 3). Ubiquitin ligases polyubiquitinate substrates directed for 26S 
proteasome degradation and inappropriate proteasomal degradation may be one of the 
causative effects of neurodegeneration[18, 19]. miR-335-5p and miR-6865-3p may affect 
the ubiquitin pathway having an impact on neurodegeneration.  
The PARKmiRs also appear to regulate other key cellular enzymes. For example, 
miR-335-5p and miR-6865-3p overexpression downregulate phosphatase ppp1r18[20], 
whereas miR-6865-3p and miR-3613-3p upregulate ppp4r1, a serine/threonine-protein 
phosphatase 4 regulatory subunit 1[21] (Supplemental Table 3). Numerous phosphatases 
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and regulatory subunits contribute to cell survival and PARKmiRs may regulate 
phosphatases influencing neurodegeneration[22].  
miR-6865-3p overexpression also increases fkbp10 levels (Supplemental Table 3), a 
peptidyl-prolyl cis-trans isomerase influencing protein folding[23], and decreases hspb8 
(Supplemental Table 3) which stimulates clearance of proteins prone to aggregation in 
neurodegenerative diseases[24]. miR-6865-3p overexpression downregulates syntaxin-16 
levels, a t-SNARE family member (Supplemental Table 3) and SNARE complex 
assembly is promoted by a-syn[25]. 
Our data suggests that the serum PARKmiR signatures may not only be valuable as 







Our study has shown that combinatory miRNA signatures in serum can act as robust 
classifiers of PD and that these miRNA signatures regulate PD-associated proteins, 
including a-syn and LRRK2. We have shown that a combination of miRNAs hsa-miR-
335-5p, hsa-miR-3613-3p, and hsa-miR-6865-3p (PARKmiRs) can differentiate between 
PD and control serum in a large 370 PD patient and control longitudinal cohort at 
baseline. Furthermore, these PARKmiR signatures were validated in an independent 64 
PD patient and control longitudinal cohort. In addition, the PARKmiR signatures were 
shown to have specificity towards PD as they exhibit different characteristics in AD 
serum samples. It is important to note that sequence similarities between the miR-520 and 
miR-548 families caused unsuccessful qRT-PCR analysis. Further the qRT-PCR data for 
some of the initial 23 candidate miRNAs in the affymetrix screen showed intergroup 
variation that resulted in statistically insignificant fold changes. These factors highlight 
the refinement of the initial 23 putative miRNAs into the more robust 3 PARKmiRs. 
Previous studies that have shown differential abundance of miRNAs in biofluids from 
PD and control samples are inconsistent with very few common candidate miRNAs 
amongst these studies[3, 6, 8-10]. This is mainly because of the small cohort sizes 
employed, the characterization of single miRNAs, and importantly the lack of 
independent validation studies[3, 10]. The importance of using samples at the time of 
diagnosis (baseline) from at least two independent prospective population-based 
longitudinal cohorts, in defining and characterizing miRNAs as potential biomarkers, 
cannot be over emphasized. In general, PD patients undergo a wide variety of 
pharmacological treatments involving multiple drugs in varying dosage[26] and biofluids 
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collected for biomarker discovery post-treatment tend to produce inconsistent results that 
cannot be validated in independent cohorts. The most compelling study to date used 102 
whole blood PD samples reporting altered expression of miRNAs, however the study 
only screened for miRNAs associated with LRRK2[27]. Interestingly, a few studies have 
detected interesting miRNAs but the sample origin and type of biofluid makes it 
challenging to connect the findings [3]. Furthermore, Martins and colleagues found that 
miR-335-5p, is down-regulated in peripheral blood mononuclear cells (PBMCs) as 
compared to the present study showing upregulation in serum [9]. The observed 
differences in miR-335-5p levels can most likely be attributed to the different clinical 
samples used for the miRNA extraction. 
Our study has also highlighted that changes in single miRNA profiles, between 
control and PD patient serum samples, may not act as robust classifiers of disease. For 
example, although miR-335-5p alone distinguished PD serum from control serum in the 
ParkWest cohort (AUC 0.90, 95% CI 0.87 to 0.93), miR-335-5p was unable to 
differentiate PD from control serum (AUC 0.62, p = 0.125) in the NYPUM cohort 
(Supplemental Fig. 1). In contrast, PARKmiR combinations acted as good classifiers 
across different cohorts suggesting that combinatory miRNA signatures show more 
promise as complementary diagnostic tools for PD (Fig. 1 and Fig. 2).  
Based on our PARKmiR protein target discovery (Fig. 4) it may be that miRNA 
serum profiles in PD could give insight into cellular abnormalities in brain tissue. Indeed, 
previous studies have suggested that altered miRNA levels in brain tissue are associated 
with disease pathogenesis[3, 4, 28]. The experimental verification of the predicted targets 
a-syn and LRRK2 by miR-335-5p and and miR-3613-3p, respectively, complements this 
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notion (Fig. 4). The LC-MS analysis also revealed the differential expression of many 
neurodegeneration-associated proteins in response to the PARKmiR mimics, which may 
shed light on new protein targets in PD pathogenesis. It is important to note that the exact 
source (tissue or organ) of miRNAs present in biofluids is unclear. Because of this it is 
challenging to correlate serum miRNA changes in biofluids with functionality in the 
brain.. 
Further work will be required to determine how robust the identified miRNA 
signatures are across additional geographically and ethnically diverse cohorts. It is likely 
that additional screening is needed to identify supplementary signatures in order to 
capture the full heterogeneity of PD. Furthermore the PARKmiRs should be tested in 
other related synucleinopathies like DLB, to ensure the specificity. Also, because of the 
heterogeneity of PD we envisage a matrix approach for diagnostic biomarkers where 
miRNA signatures will represent one class of molecules alongside current diagnostic 
practices and other biochemical and cellular components.    
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Fig. 1. Confirmation and verification of PARKmiRs by qRT-PCR. (A) qRT-PCR 
analysis of miR-3613-3p, miR-6865-3p and miR-335-5p in 16 PD patients compared to 
eight control serum samples. ROC analysis of qRT-PCR data from 164 PD patients 
compared to 182 control serum samples from the Norwegian ParkWest study for 
combination of miR-335-5p/miR-3613-3p (B), miR-3613-3p/miR-6865-3p (C), miR-335-
5p/miR-6865-3p (D) and miR-335-5p/miR-3613-3p/miR-6865-3p (E). (F) Statistical 
analysis (ROC) for PARKmiR combinations. Error bars indicate SEM n = 8 (control), 16 
(PD); *, p < 0.05, **, p < 0.01. 
 
Fig. 2. Validation of PARKmiRs by qRT-PCR. ROC analysis of qRT-PCR data from 42 
PD patients compared to 22 control serum samples from the NYPUM study for 
combination of miR-335-5p/miR-3613-3p (A), miR-3613-3p/miR-6865-3p (B), miR-
335-5p/miR-6865-3p (C) and miR-335-5p/miR-3613-3p/miR-6865-3p (D). (E) Statistical 
analysis (ROC) for PARKmiR combinations. 
 
Fig. 3. Specificity of PARKmiR combinations. Plot for qRT-PCR data showing distinct 
expression patterns observed for PARKmiR combinations in 164 PD patient and 48 AD 
patient serum samples as compared to 182 control serum samples. 
 
Fig. 4. Overexpression and inhibition of PARKmiRs and their effect on LRRK2 and a-
syn. (A, D, H) qRT-PCR analysis showing miR-335-5p (A), miR-3613-3p (D) and miR-
6865-3p (H) in response to mimic and antagomir. (B, C) Western blot analysis showing 
25 
 
effect of miR-335-5p on LRRK2 expression in SH-SY5Y cells. (E - G) Western blot 
analysis (E, F) and qRT-PCR analysis (G) showing effect of miR-3613-3p on a-syn 
(SNCA) expression in SH-SY5Y cells. Error bars indicate SEM (n = 3 (F, G), n = 4 (A, 
C, D, H) *, p < 0.05, **, p < 0.01; ***, p < 0.001. 
 
